Over the last fifteen years it has become established that 22q11.2 deletion syndrome (22q11DS) is a true genetic risk factor for schizophrenia. Carriers of deletions in chromosome 22q11.2 develop schizophrenia at rate of 25-30% and such deletions account for as many as 1-2% of cases of sporadic schizophrenia in the general population. Access to a relatively homogeneous population of individuals that suffer from schizophrenia as the result of a shared etiological factor and the potential to generate etiologically valid mouse models provides an immense opportunity to better understand the pathobiology of this disease. In this review we survey the clinical literature associated with the 22q11.2 microdeletions with a focus on neuroanatomical changes. Then, we highlight results from work modeling this structural mutation in animals. The key biological pathways disrupted by the mutation are discussed and how these changes impact the structure and function of neural circuits is described.
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Introduction
One approach to understanding how schizophrenia is caused in general is to focus on specific cases where the disease is caused by a known factor. Although rare, there are now a number of instances where the primary genetic causative factor appears to have been identified (Karayiorgou et al., 1995; Millar et al., 2000; Xu et al., 2009 ). Here, we discuss the example of genomic microdeletions in the chromosomal region 22q11.2 that may account for as many as 1-2% of cases of schizophrenia (Karayiorgou et al., 2010) and is, to date, the only confirmed recurrent structural mutation responsible for the introduction of sporadic cases of schizophrenia.
The identification, fifteen years ago, of 22q11.2 microdeletions as a causative factor for schizophrenia was the first demonstration that deletions, or duplications, of chromosomal regions may play an important role in schizophrenia etiology in many cases of the disease (Karayiorgou et al., 1995) . Such mutations, known as copy number variations (CNVs), result in altered gene dosage and a rapidly expanding literature shows a high prevalence of such mutations in schizophrenia patients (International Schizophrenia Consortium, 2008; Stefansson et al., 2008; Xu et al., 2008 Xu et al., , 2009 Walsh et al., 2008) . By allowing the generation of etiological valid animal models, identification of highly penetrant mutations such as these offer unprecedented opportunities to determine the key neural changes that can lead to psychotic illness (Arguello and Gogos, 2006). Here we argue that the 22q11.2 deletion can act as prototype for this type of investigation. That is to say, the rigorous definition of the pathway from mutation to disease phenotype in models of this mutation will provide invaluable insights into the etiology and pathophysiology of schizophrenia as a whole.
